The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Long-term follow-up from a Phase II trial of olutasidenib in IDH1-mutated AML
Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, discusses the long-term follow-up results from the Phase II trial of olutasidenib in IDH1-mutated acute myeloid leukemia (AML). He highlights a 35% response rate with significant durability of response, lasting more than two years. He notes no new adverse events or late toxicities, emphasizing that more than 50% of patients continue on therapy for three to four years, maintaining their response. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The olutasidenib longer term follow up has continued to demonstrate the benefit of the drug. The response rate hasn’t changed with the longer term follow up, all the responses have been within a month or two. We get about 35% response rate, most of these are CRs, 32% are CR. But what we continue seeing is the durability of the responses – it’s more than two years, the duration of response...
The olutasidenib longer term follow up has continued to demonstrate the benefit of the drug. The response rate hasn’t changed with the longer term follow up, all the responses have been within a month or two. We get about 35% response rate, most of these are CRs, 32% are CR. But what we continue seeing is the durability of the responses – it’s more than two years, the duration of response. The survival benefit is significant. So I think it provides – the other thing that’s important is we have not seen any more, any new adverse events, there’s no late differentiation syndrome, of course, there’s no late QTc prolongation; olutasidenib has very little QTc prolongation anyway, and we don’t see any more with prolonged use. We don’t see hardly any late liver toxicity, that’s the one biggest concern in terms of safety. But really all of them happen early on. So again the continued administration is very good. More than 50% of patients continue on therapy and maintaining their response by three or four years (of the responders). So that shows that these responses even with single agent olutasidenib can be very, very durable. So great benefit for these patients.
Read more...
